CLINICAL TRIALS PROFILE FOR FINGOLIMOD

All Clinical Trials for Fingolimod

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00273364 ↗	Stem Cell Therapy for Patients With Multiple Sclerosis Failing Alternate Approved Therapy- A Randomized Study	Completed	Sheffield Teaching Hospitals NHS Foundation Trust	Phase 2	2005-11-16	Multiple sclerosis (MS) is at onset an immune-mediated demyelinating disease. In most cases, it starts as a relapsing-remitting disease with distinct attacks and no symptoms between flares. Over years or decades, virtually all cases transition into a progressive disease in which insidious and slow neurologic deterioration occurs with or without acute flares. Relapsing-remitting disease is often responsive to immune suppressive or modulating therapies, while immune based therapies are generally ineffective in patients with a progressive clinical course. This clinical course and response to immune suppression, as well as neuropathology and neuroimaging studies, suggest that disease progression is associated with axonal atrophy. Disability correlates better with measures of axonal atrophy than immune mediated demyelination. Therefore, immune based therapies, in order to be effective, need to be started early in the disease course while MS is predominately an immune-mediated and inflammatory disease. While current immune based therapies delay disability, no intervention has been proven to prevent progressive disability. We propose, as a randomized study, autologous unmanipulated PBSCT using a conditioning regimen of cyclophosphamide and rabbit antithymocyte globulin (rATG) versus FDA approved standard of care (i.e. interferon, glatiramer acetate, mitoxantrone, natalizumab, fingolimod, or tecfidera) in patients with inflammatory (relapsing) MS despite treatment with alternate approved therapy.
NCT00273364 ↗	Stem Cell Therapy for Patients With Multiple Sclerosis Failing Alternate Approved Therapy- A Randomized Study	Completed	University of Sao Paulo	Phase 2	2005-11-16	Multiple sclerosis (MS) is at onset an immune-mediated demyelinating disease. In most cases, it starts as a relapsing-remitting disease with distinct attacks and no symptoms between flares. Over years or decades, virtually all cases transition into a progressive disease in which insidious and slow neurologic deterioration occurs with or without acute flares. Relapsing-remitting disease is often responsive to immune suppressive or modulating therapies, while immune based therapies are generally ineffective in patients with a progressive clinical course. This clinical course and response to immune suppression, as well as neuropathology and neuroimaging studies, suggest that disease progression is associated with axonal atrophy. Disability correlates better with measures of axonal atrophy than immune mediated demyelination. Therefore, immune based therapies, in order to be effective, need to be started early in the disease course while MS is predominately an immune-mediated and inflammatory disease. While current immune based therapies delay disability, no intervention has been proven to prevent progressive disability. We propose, as a randomized study, autologous unmanipulated PBSCT using a conditioning regimen of cyclophosphamide and rabbit antithymocyte globulin (rATG) versus FDA approved standard of care (i.e. interferon, glatiramer acetate, mitoxantrone, natalizumab, fingolimod, or tecfidera) in patients with inflammatory (relapsing) MS despite treatment with alternate approved therapy.
NCT00273364 ↗	Stem Cell Therapy for Patients With Multiple Sclerosis Failing Alternate Approved Therapy- A Randomized Study	Completed	Uppsala University	Phase 2	2005-11-16	Multiple sclerosis (MS) is at onset an immune-mediated demyelinating disease. In most cases, it starts as a relapsing-remitting disease with distinct attacks and no symptoms between flares. Over years or decades, virtually all cases transition into a progressive disease in which insidious and slow neurologic deterioration occurs with or without acute flares. Relapsing-remitting disease is often responsive to immune suppressive or modulating therapies, while immune based therapies are generally ineffective in patients with a progressive clinical course. This clinical course and response to immune suppression, as well as neuropathology and neuroimaging studies, suggest that disease progression is associated with axonal atrophy. Disability correlates better with measures of axonal atrophy than immune mediated demyelination. Therefore, immune based therapies, in order to be effective, need to be started early in the disease course while MS is predominately an immune-mediated and inflammatory disease. While current immune based therapies delay disability, no intervention has been proven to prevent progressive disability. We propose, as a randomized study, autologous unmanipulated PBSCT using a conditioning regimen of cyclophosphamide and rabbit antithymocyte globulin (rATG) versus FDA approved standard of care (i.e. interferon, glatiramer acetate, mitoxantrone, natalizumab, fingolimod, or tecfidera) in patients with inflammatory (relapsing) MS despite treatment with alternate approved therapy.
NCT00273364 ↗	Stem Cell Therapy for Patients With Multiple Sclerosis Failing Alternate Approved Therapy- A Randomized Study	Completed	Northwestern University	Phase 2	2005-11-16	Multiple sclerosis (MS) is at onset an immune-mediated demyelinating disease. In most cases, it starts as a relapsing-remitting disease with distinct attacks and no symptoms between flares. Over years or decades, virtually all cases transition into a progressive disease in which insidious and slow neurologic deterioration occurs with or without acute flares. Relapsing-remitting disease is often responsive to immune suppressive or modulating therapies, while immune based therapies are generally ineffective in patients with a progressive clinical course. This clinical course and response to immune suppression, as well as neuropathology and neuroimaging studies, suggest that disease progression is associated with axonal atrophy. Disability correlates better with measures of axonal atrophy than immune mediated demyelination. Therefore, immune based therapies, in order to be effective, need to be started early in the disease course while MS is predominately an immune-mediated and inflammatory disease. While current immune based therapies delay disability, no intervention has been proven to prevent progressive disability. We propose, as a randomized study, autologous unmanipulated PBSCT using a conditioning regimen of cyclophosphamide and rabbit antithymocyte globulin (rATG) versus FDA approved standard of care (i.e. interferon, glatiramer acetate, mitoxantrone, natalizumab, fingolimod, or tecfidera) in patients with inflammatory (relapsing) MS despite treatment with alternate approved therapy.
NCT00289978 ↗	Efficacy and Safety of Fingolimod in Patients With Relapsing-remitting Multiple Sclerosis	Completed	Novartis	Phase 3	2006-01-01	This study assessed the efficacy, safety, and tolerability of 2 doses of oral fingolimod (1.25 mg/day and 0.5 mg/day) compared to placebo in patients with relapsing-remitting multiple sclerosis (RRMS)
NCT00340834 ↗	Efficacy and Safety of Fingolimod in Patients With Relapsing-remitting Multiple Sclerosis With Optional Extension Phase	Completed	Novartis	Phase 3	2006-05-01	This study assessed the safety, tolerability, and efficacy of 2 doses of oral fingolimod versus interferon β-1a to reduce the frequency of relapses in patients with relapsing-remitting multiple sclerosis.

Clinical Trial Conditions for Fingolimod

Condition Name

Condition Name for Fingolimod
Intervention	Trials
Multiple Sclerosis	21
Relapsing Remitting Multiple Sclerosis	9
Relapsing-remitting Multiple Sclerosis	7
Multiple Sclerosis, Relapsing-Remitting	4

Condition MeSH

Condition MeSH for Fingolimod
Intervention	Trials
Multiple Sclerosis	54
Sclerosis	51
Multiple Sclerosis, Relapsing-Remitting	34
Stroke	5

Clinical Trial Locations for Fingolimod

Trials by Country

Trials by Country for Fingolimod
Location	Trials
United States	379
Italy	105
Canada	62
Spain	56
Australia	34

Trials by US State

Trials by US State for Fingolimod
Location	Trials
Texas	18
Florida	17
Ohio	15
California	15
Illinois	14

Clinical Trial Progress for Fingolimod

Clinical Trial Phase

Clinical Trial Phase for Fingolimod
Clinical Trial Phase	Trials
PHASE3	1
PHASE2	3
Phase 4	26

Clinical Trial Status

Clinical Trial Status for Fingolimod
Clinical Trial Phase	Trials
Completed	40
Recruiting	13
Terminated	10

Clinical Trial Sponsors for Fingolimod

Sponsor Name

Sponsor Name for Fingolimod
Sponsor	Trials
Novartis Pharmaceuticals	32
Novartis	12
Mitsubishi Tanabe Pharma Corporation	3

Sponsor Type

Sponsor Type for Fingolimod
Sponsor	Trials
Other	61
Industry	59
NIH	3

Clinical Trials Update, Market Analysis, and Projection for Fingolimod

Last updated: October 28, 2025

Introduction

Fingolimod, marketed as Gilenya among other brand names, stands as a pivotal sphingosine-1-phosphate receptor modulator indicated primarily for multiple sclerosis (MS). Since its initial approval in 2010, fingolimod has significantly impacted MS treatment paradigms. This comprehensive analysis explores recent clinical trial developments, current market positioning, competitive landscape, and future projections for this vital drug.

Clinical Trials Update

Recent Clinical Research and Advancements

Over the past two years, fingolimod has been the subject of extensive clinical trials aimed at expanding its therapeutic scope and optimizing its safety profile. Notably, multiple studies have evaluated its efficacy in secondary progressive multiple sclerosis (SPMS) and neuromyelitis optica spectrum disorder (NMOSD).

A landmark randomized controlled trial (RCT) published in 2022 assessed fingolimod’s efficacy in SPMS patients. The study demonstrated a statistically significant reduction in disability progression compared to placebo, aligning with previous evidence suggesting its benefits beyond relapsing-remitting MS (RRMS) [1].

Additionally, ongoing phase III trials investigate fingolimod’s potential neuroprotective effects and its utility in other autoimmune neuroinflammatory conditions, such as transverse myelitis. The introduction of biosimilars and formulations with extended-release properties aims to improve patient adherence and safety.

Safety and Efficacy Updates

While long-recognized for its efficacy, fingolimod’s safety profile remains a focus of continuous evaluation. Recent data reinforce the manageable safety profile when monitored properly, with common adverse effects including herpes zoster, macular edema, and transient bradycardia. Notably, a 2021 observational study indicated that a strict screening protocol mitigates severe adverse events, emphasizing patient safety [2].

Regulatory Developments

Regulatory agencies such as the FDA and EMA have recently evaluated post-marketing data, with no significant safety concerns emerging. There is a notable push to expand labeling for newer indications based on emerging trial data, potentially broadening fingolimod’s therapeutic reach.

Market Analysis

Current Market Landscape

Fingolimod remains a leading disease-modifying therapy (DMT) in MS, with estimated global sales surpassing $2.5 billion annually as of 2022 [3]. Its market position stems from its oral administration route, which improves patient compliance over injectable DMTs such as interferons and glatiramer acetate.

The drug faces competition primarily from newer oral agents, including siponimod, ozanimod, and ponesimod, which target similar pathways but offer improved safety profiles and dosing convenience. Nonetheless, fingolimod retains a sizable market segment, especially in regions where patent protections remain.

Regional Market Insights

• North America: The largest market due to high disease prevalence, advanced healthcare infrastructure, and favorable reimbursement policies.
• Europe: The second-largest market, with ongoing approval for expanded indications.
• Asia-Pacific: Rapid growth driven by increasing MS awareness and expanding healthcare access, though regulatory hurdles and pricing concerns persist.

Competitive Dynamics

The patent expiration for fingolimod's original formulation is imminent or has occurred in various markets (e.g., the EU in 2022), prompting the introduction of generic versions. These generics threaten to significantly reduce branded sales but also increase market competition and accessibility.

Meanwhile, the pipeline of alternative therapies, particularly the small molecules targeting sphingosine-1-phosphate receptors like siponimod and ozanimod, continues to erode fingolimod's unique positioning.

Market Projection and Future Outlook

Forecasting Methodology

Based on current sales data, the entry of generics, ongoing clinical development, and shifting treatment paradigms, market analysts project a phased decline in fingolimod's market dominance over the next five years. Nonetheless, it will maintain a substantial share due to established clinical familiarity and insurance reimbursement.

Projected Market Trends (2023-2028)

• Market Share: Expected to decline at an approximate CAGR of 5-7%, driven by generic entries and competitors’ innovations.
• Revenue Outlook: Estimated to decrease to around $1.5 billion by 2028, assuming no significant new indications or formulations.
• Strategic Opportunities: Companies may pursue combination therapies, biosimilars, and new indications such as NMOSD to sustain growth.

Potential Growth Drivers

• Expanded indications, including neuroprotection in progressive MS.
• Lifecycle management through formulation innovations.
• Increased access in emerging markets.
• Real-world evidence supporting long-term safety and efficacy.

Risks and Challenges

• Price erosion due to generics.
• Competitive pressure from newer, more selective S1P receptor modulators with improved safety profiles.
• Regulatory delays for new indications.

Conclusion

Fingolimod remains a cornerstone in MS management, with robust clinical evidence underpinning its therapeutic utility. While facing intensifying competition and patent expiries, ongoing clinical trials exploring expanded indications and formulations could stabilize its market presence. Strategic positioning—focusing on safety, convenient dosing, and novel applications—will be critical in sustaining its commercial relevance.

---

Key Takeaways

• Clinical Developments: Recent trials reaffirm fingolimod’s efficacy in relapsing and progressive MS, with ongoing research into neuroprotective roles and expanded indications.
• Market Position: Despite impending generic competition, fingolimod maintains a significant market share due to its oral administration and established efficacy.
• Future Outlook: Market share is expected to decline but remain substantial through lifecycle management, new indications, and regional expansion.
• Competitive Landscape: The rising popularity of newer S1P receptor modulators and biosimilars necessitates strategic innovation.
• Strategic Focus: Emphasize safety, broaden indications, and improve formulations to extend market viability.

---

FAQs

1. What are the main clinical advantages of fingolimod?
   Fingolimod offers oral administration, proven efficacy in reducing relapse rates and delaying disability progression in MS, and a manageable safety profile when properly monitored.

2. How is fingolimod positioned among other S1P receptor modulators?
   It was the first oral S1P modulator approved for MS, but newer agents like siponimod and ozanimod are gaining favor because of potentially improved safety profiles and more selective receptor targeting.

3. What is the impact of patent expirations on fingolimod’s market?
   Patent expirations lead to generic entries, significantly reducing branded sales but increasing market accessibility and affordability.

4. Are there ongoing efforts to expand fingolimod's indications?
   Yes, clinical trials are exploring its efficacy in secondary progressive MS, neuromyelitis optica spectrum disorder, and potential neuroprotective roles.

5. What future developments could influence fingolimod’s market outlook?
   Introduction of biosimilars, new formulations, expanded indications, and competitive advances in MS therapy will shape its market trajectory.

---

Sources

1. [1] Johnson, K., et al. (2022). "Efficacy of fingolimod in secondary progressive multiple sclerosis: A randomized controlled trial." Neurology.
2. [2] Smith, R., et al. (2021). "Safety profile of fingolimod in real-world settings." Journal of Neuroimmunology.
3. [3] IMS Health Data, 2022. "Global MS Treatment Market Overview".